Intradermal Needle Therapy for Major Depressive Disorder
27 de abril de 2022 actualizado por: Xiaomei Shao, The Third Affiliated hospital of Zhejiang Chinese Medical University
Major depressive disorder (MDD) is a common mental disorder that affects patients' physical health and quality of life.
Although traditional acupuncture therapy has certain advantages in improving MDD, there are still some limitations, such as being time-consuming and some people having a fear of acupuncture.
Therefore, intradermal needle therapy will be chosen in the treatment of MDD in this study, which is more convenient, shallow needling, and gentle than traditional acupuncture therapy.
The study is designed to investigate the therapeutic effect and safety of intradermal needles for MDD.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Intervención / Tratamiento
Descripción detallada
A total of 120 participants with MDD who meet the inclusion criteria will be included in the study.
Participants will be randomly divided into the SSRIs + acupuncture group, acupuncture + placebo group, and SSRIs + sham acupuncture group.
This study will evaluate the efficacy and safety of the intradermal needle for MDD and investigate whether the intradermal needle reduces side effects and increases the efficacy of selective serotonin reuptake inhibitors (SSRIs) antidepressants for MDD.
Furthermore, the study will demonstrate whether the intradermal needle has a synergistic effect with SSRIs on the treatment of MDD.
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
120
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Xiaomei M Shao, Ph.D
- Número de teléfono: +8618957130287
- Correo electrónico: shaoxiaomei@zcmu.edu.cn
Ubicaciones de estudio
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana
- Xiaomei Medical Shao
-
Contacto:
- Xiaomei M Shao
- Número de teléfono: +8618957130287
- Correo electrónico: shaoxiaomei@zcmu.edu.cn
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
12 años a 60 años (Niño, Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- 1. Patients should meet the diagnostic criteria of the International Classification of Diseases 10th Edition (ICD-10) diagnostic criteria for depression and are evaluated as moderate or severe MDD according to the severity of depression; 2. 12 ≤ age ≤60, male or female; 3. Participants have clear consciousness and could communicate with others normally; 4. Participants could understand the full study protocol and have high adherence. Written informed consent is signed by themselves or their lineal kin (for minor participants, their guardian should sign the informed consent form for them).
Exclusion Criteria:
- 1. Participants with serious primary diseases of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, neurological disease, and other serious primary diseases, and the disease cannot be effectively controlled clinically; 2. Major depressive disorders caused by organic mental disorders, schizophrenia, bipolar disorder, psychoactive substances, and non-addictive substances; 3. Participants with suicidal tendencies; 4. Pregnant or lactating participants; 5. Participants taking other antidepressants that were not SSRIs or the pharmacological effects of such antidepressants have not been cleared; 6. Participants with intellectual disabilities who cannot cooperate with the questionnaire survey; 7. Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape; 8. Participants are participating in other trials.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: acupuncture + SSRIs group
This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants.
Acupoints related to MDD will be stimulated.
The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
|
SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist.
Once-daily for 6 weeks.
Otros nombres:
This study will use the intradermal needle as an acupuncture intervention.
Acupoints related to MDD will be stimulated.
According to the position of the acupoints, choose a needle of φ0.20*1.5m
or φ0.20*1.2mm.
Press the needle to insert the acupoint vertically and retain it in the skin.
After the intervention, the needle will be retained for 72 hours with a day of rest after removal.
During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours.
A total of 10 treatment sessions will be performed for 6 weeks.
Otros nombres:
|
|
Experimental: acupuncture + placebo group
This group will include 40 patients with MDD who will be treated with acupuncture and a placebo.
Acupoints related to MDD will be stimulated.
The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
|
This study will use the intradermal needle as an acupuncture intervention.
Acupoints related to MDD will be stimulated.
According to the position of the acupoints, choose a needle of φ0.20*1.5m
or φ0.20*1.2mm.
Press the needle to insert the acupoint vertically and retain it in the skin.
After the intervention, the needle will be retained for 72 hours with a day of rest after removal.
During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours.
A total of 10 treatment sessions will be performed for 6 weeks.
Otros nombres:
Oral placebo mimicking SSRIs antidepressants.
Once-daily for 6 weeks.
Otros nombres:
|
|
Experimental: sham acupuncture + SSRIs group
This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants.
The sham acupuncture will be needled on the points 1cm lateral to acupoints.
The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
|
SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist.
Once-daily for 6 weeks.
Otros nombres:
Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body.
The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints.
After the intervention, the needle will be retained for 72 hours with a day of rest after removal.
A total of 10 sessions will be performed for 6 weeks.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in the Hamilton Depression Scale-17 (HAMD-17)
Periodo de tiempo: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
The HAMD scale is the most commonly used in the clinical assessment of depression, including 17 items.
The higher the score, the more severe the depression.
0-7 means no depressive symptoms, 8-17 means mild depression, 18-24 was divided into moderate depression, and 25-52 was divided into severe depression.
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in the Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
The PSQI is used to assess the sleep quality of the participant in the last 1 month and consisted of 19 self-rated and 5 other rated items.
The higher the score, the worse the sleep quality.
Sleep quality is divided into 4 levels according to the total score.
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
|
Change in the Treatment Emergent SymptomScale (TESS)
Periodo de tiempo: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
The TESS scale rated each symptom on three dimensions: severity, the relationship between the symptom and the medication, and the measure taken.
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
|
Change in the MOS item short from health survey (SF-36)
Periodo de tiempo: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
The SF-36 scale evaluates the quality of healthy life into 8 dimensions, which are divided into two categories: physical health and mental health, namely physical function (PF), role physical (RP), body pain (BP), general health (GH), vitality (VT), social function (SF), role emotional (RE), mental health (MH).
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Colaboradores
Investigadores
- Investigador principal: Xiaomei M Shao, Ph.D, The Third Affiliated hospital of Zhejiang Chinese Medical University
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Anticipado)
1 de mayo de 2022
Finalización primaria (Anticipado)
1 de mayo de 2025
Finalización del estudio (Anticipado)
30 de diciembre de 2025
Fechas de registro del estudio
Enviado por primera vez
27 de abril de 2022
Primero enviado que cumplió con los criterios de control de calidad
27 de abril de 2022
Publicado por primera vez (Actual)
28 de abril de 2022
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
28 de abril de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
27 de abril de 2022
Última verificación
1 de abril de 2022
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2022ZX010-MDD
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .